Adlai Nortye Ltd. ADR

Adlai Nortye Ltd. ADR is the American Depositary Receipt representing shares of Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapies. The company leverages its dual R&D presence in the United States and China to advance a robust pipeline of drug candidates targeting two critical areas in oncology. In next-generation cancer immunotherapies, it features AN8025, a tri-functional fusion protein combining αPD-L1, CD86 variant, and LAG3 variant to modulate T-cells and antigen-presenting cells, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor designed to activate cancer immunity through novel mechanisms. For RAS-targeting therapies addressing RAS-driven cancers, its candidates include AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a potent pan-RAS(ON) inhibitor directly to tumors. Adlai Nortye Ltd., incorporated in 2018 and headquartered in North Brunswick Township, New Jersey, plays a significant role in the immuno-oncology sector by focusing on differentiated medicines for a broad spectrum of tumor types.